Ignite Creation Date:
2025-12-24 @ 2:52 PM
Ignite Modification Date:
2026-02-10 @ 5:08 AM
Study NCT ID:
NCT06162559
Status:
RECRUITING
Last Update Posted:
2024-01-11
First Post:
2023-11-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
Sponsor:
The Netherlands Cancer Institute
Organization: